CD274 and familial pancreatic carcinoma: A similar clinical benefit was recently reported in a case study of metastatic pancreatic cancer patients treated with combined NK cell infusion and PD-1 blockade.36 We hypothesize that PD-1/PD-L1 blockade may directly reinvigorate the intratumoral NK cell response.37,38 Furthermore, our transcriptomic profiling revealed that NK cell combination therapy induces a proinflammatory, T-cell-activated microenvironment in responders, suggesting that this immune-remodeling niche may indirectly prime tumors for increased sensitivity to PD-1 inhibition.